Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions

Neurochemistry International

Volumn 55, Issue 7, 2009, Pages 606-609

  Kéri, Szabolcs ^a   Seres, Imola ^a   Kelemen, Oguz ^b   Benedek, György ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

AKT; Cognition; Neuregulin 1; Schizophrenia

Indexed keywords

ESCITALOPRAM; FLUPENTIXOL; LITHIUM SALT; NEU DIFFERENTIATION FACTOR; OLANZAPINE; PROTEIN KINASE B; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; ARTICLE; ATTENTION; B LYMPHOBLAST; CELL STIMULATION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LANGUAGE; LONG TERM MEMORY; MALE; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ISOLATION; PSYCHOSIS; SCHIZOPHRENIA; SKILL; WESTERN BLOTTING;

ADULT; B-LYMPHOCYTES; BIOLOGICAL MARKERS; COGNITION; FEMALE; HUMANS; MALE; NEUREGULIN-1; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STIMULATION, CHEMICAL;

EID: 69349099464     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.06.002     Document Type: Article

References (31)

1. Ditlevsen D.K., Owczarek S., Berezin V., and Bock E. Relative role of upstream regulators of Akt, ERK and CREB in NCAM- and FGF2-mediated signalling. Neurochem. Int. 53 (2008) 137-147
2. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
3. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) (1996), American Psychiatrc Press, Washington, DC
4. Gold J.M., Queern C., Iannone V.N., and Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia. I. Sensitivity, reliability, and validity. Am. J. Psychiatry 156 (1999) 1944-1950
5. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 (2000) 119-136
6. Hall J., Whalley H.C., Job D.E., Baig B.J., McIntosh A.M., Evans K.L., Thomson P.A., Porteous D.J., Cunningham-Owens D.G., Johnstone E.C., and Lawrie S.M. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat. Neurosci. 9 (2006) 1477-1478
7. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 60 (2006) 132-140
8. Howlett E., Lin C.C., Lavery W., and Stern M. A PI3-kinase-mediated negative feedback regulates neuronal excitability. PLoS Genet. 4 (2008) e1000277
9. Ide M., Ohnishi T., Murayama M., Matsumoto I., Yamada K., Iwayama Y., Dedova I., Toyota T., Asada T., Takashima A., and Yoshikawa T. Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J. Neurochem. 99 (2006) 277-287
10. Kanakry C.G., Li Z., Nakai Y., Sei Y., and Weinberger D.R. Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS ONE 26 (2007) e1369
11. Kéri S., Kiss I., and Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high-risk for psychosis. Mol. Psychiatry 14 (2009) 118-119
12. Kéri, S., Seres, I., Kelemen, O., Benedek, G., in press. The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in non-clinical individuals. Schizophr. Bull.
13. Kondziella D., Brenner E., Eyjolfsson E.M., and Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem. Int. 50 (2007) 291-301
14. Lai W.S., Xu B., Westphal K.G., Paterlini M., Olivier B., Pavlidis P., Karayiorgou M., and Gogos J.A. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 16906-16911
15. Marmor M.D., Skaria K.B., and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 903-913
16. Matsuzaki S., and Tohyama M. Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). Neurochem. Int. 52 (2007) 165-172
17. Mei L., and Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 9 (2008) 437-452
18. Mouri A., Noda Y., Enomoto T., and Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 51 (2007) 173-184
19. Munafò M.R., Thiselton D.L., Clark T.G., and Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol. Psychiatry 11 (2006) 539-546
20. Nadri C., Belmaker R.H., and Agam G. Oxygen restriction of neonate rats elevates neuregulin-1alpha isoform levels: possible relationship to schizophrenia. Neurochem. Int. 51 (2007) 447-450
21. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Harvey R., and Waddington J.L. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147 (2007) 18-27
22. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status (1998), The Psychological, San Antonio, TX
23. Reichenberg A., and Harvey P.D. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol. Bull. 133 (2007) 833-858
24. Rhoades H.V., and Overall J.E. The semistructured BPRS interview and rating guide. Psychopharmacol. Bull. 24 (1988) 101-104
25. Rujescu D., Ingason A., Cichon S., Pietiläinen O.P., Barnes M.R., Toulopoulou T., Picchioni M., Vassos E., Ettinger U., Bramon E., Murray R., Ruggeri M., Tosato S., Bonetto C., Steinberg S., Sigurdsson E., Sigmundsson T., Petursson H., Gylfason A., Olason P.I., Hardarsson G., Jonsdottir G.A., Gustafsson O., Fossdal R., Giegling I., Möller H.J., Hartmann A.M., Hoffmann P., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Djurovic S., Melle I., Andreassen O.A., Hansen T., Werge T., Kiemeney L.A., Franke B., Veltman J., Buizer-Voskamp J.E., Investigators GROUP., Sabatti C., Ophoff R.A., Rietschel M., Nöthen M.M., Stefansson K., Peltonen L., St Clair D., Stefansson H., and Collier D.A. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 18 (2009) 988-996
26. Schmitt A., Parlapani E., Gruber O., Wobrock T., and Falkai P. Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur. Arch. Psychiatry Clin. Neurosci. 258 Suppl. 5 (2008) 35-39
27. Sei Y., Ren-Patterson R., Li Z., Tunbridge E.M., Egan M.F., Kolachana B.S., and Weinberger D.R. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Mol. Psychiatry 12 (2007) 946-957
28. Sershen H., Balla A., Aspromonte J.M., Xie S., Cooper T.B., and Javitt D.C. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochem. Int. 52 (2008) 119-129
29. Stefanis N.C., Trikalinos T.A., Avramopoulos D., Smyrnis N., Evdokimidis I., Ntzani E.E., Ioannidis J.P., and Stefanis C.N. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol. Psychiatry 62 (2007) 784-792
30. Tan H.Y., Nicodemus K.K., Chen Q., Li Z., Brooke J.K., Honea R., Kolachana B.S., Straub R.E., Meyer-Lindenberg A., Sei Y., Mattay V.S., Callicott J.H., and Weinberger D.R. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J. Clin. Invest. 118 (2008) 2200-2208
31. Young J.W., Powell S.B., Risbrough V., Marston H.M., and Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122 (2009) 150-202